authorisation arrangements are in Authorisation and Clinical Governance Agreed recommendations of the review are to place for high cost blood products. Framework for Intravenous be implemented from early 2014 Immunoglobulin (IVIg). Facilitate implementation of recommendations agreed by Health Ministers. 3.5 Provide advice to Health Endorse agreed benchmarks and national JBC to consider proposals from JBC about Ministers on proposed benchmarks performance measures on appropriate use, potential measures by December 2013. and national performance measures which leverage information already for appropriate use of blood and collected or available, for referral to Health blood products. Ministers. 3.6 Build and promote sharing of Support the development of blood-related BloodSafe e-learning Australia program is to knowledge and identify and promote education materials for the health develop a further three modules. best practice in clinical governance workforce and promote their national JBC to oversight the evaluation of the and practice. uptake and evaluation. effectiveness of the BloodSafe e-learning program by September 2015. JBC to provide advice to the NBA about the development of further guidelines. Monitor, and report on, implementation of NBA to publish and disseminate new Criteria. the revised Criteria for Clinical Use of JBC to monitor IVIg usage reports and IVIg. provide advice on any significant variation to estimated demand to AHPC. Support the development of a Private Sector JBC to consider NBA proposals to engage Engagement Framework and facilitate private sector hospitals and laboratories as 3.7 Improve private sector private sector interest. part of the implementation of the engagement to promote a better Statement on understanding of issues, National Stewardship Expectations for the including capacity for more efficient Supply of Blood and Blood Products) and appropriate use, in particular
authorisation arrangements are in place for high cost blood products. Authorisation and Clinical Governance Framework for Intravenous Immunoglobulin (IVIg). Facilitate implementation of recommendations agreed by Health Ministers. Agreed recommendations of the review are to be implemented from early 2014 3.5 Provide advice to Health Ministers on proposed benchmarks and national performance measures for appropriate use of blood and blood products. Endorse agreed benchmarks and national performance measures on appropriate use, which leverage information already collected or available, for referral to Health Ministers. JBC to consider proposals from JBC about potential measures by December 2013. 3.6 Build and promote sharing of knowledge and identify and promote best practice in clinical governance and practice. Support the development of blood-related education materials for the health workforce and promote their national uptake and evaluation. BloodSafe e-learning Australia program is to develop a further three modules. JBC to oversight the evaluation of the effectiveness of the BloodSafe e-learning program by September 2015. JBC to provide advice to the NBA about the development of further guidelines. Monitor, and report on, implementation of the revised Criteria for Clinical Use of IVIg. NBA to publish and disseminate new Criteria. JBC to monitor IVIg usage reports and provide advice on any significant variation to estimated demand to AHPC. 3.7 Improve private sector engagement to promote a better understanding of issues, including capacity for more efficient and appropriate use, in particular Support the development of a Private Sector Engagement Framework and facilitate private sector interest. JBC to consider NBA proposals to engage private sector hospitals and laboratories as part of the implementation of the Statement on National Stewardship Expectations for the Supply of Blood and Blood Products)
jbc-strategic-plan-2013-15.docx